Last reviewed · How we verify
NCT04299919
The AI Prognostic Assessment and Pathological Basis Research of Early HCC After Minimally Invasive Treatment
trial testing Minimally invasive treatment in Hepatocellular Carcinoma in 1,200 participants. Status unknown.
30 June 2023
Quick facts
| Lead sponsor | The First Affiliated Hospital of Dalian Medical University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 1,200 |
| Start date | 1 April 2007 |
| Primary completion | 30 June 2023 |
| Estimated completion | 30 June 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Minimally invasive treatment
- Hepatectomy
Conditions studied
- Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →
Sponsor
The First Affiliated Hospital of Dalian Medical University
Who can join
Eligibility, any sex, with Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study evaluates artificial intelligence method based on multimodal magnetic resonance imaging (MRI) images and clinical data in preoperative prediction of prognosis in early hepatocellular carcinoma (HCC) patients treated with minimally invasive treatment. The correlation between prognosis-related MRI features and pathological features was studied through artificial intelligence method, so as to provide the interpretability of image features for predicting the prognosis of HCC patients treated with minimally invasive treatment.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Bridging the Gap Between Imaging and Molecular Characterization: Current Understanding of Radiomics and Radiogenomics in Hepatocellular Carcinoma.
Ren L, Chen DB, Yan X, She S, et al · · 2024 · cited 2× · PMID 39619602 · DOI 10.2147/jhc.s423549
Verify or expand the search:
- PubMed search for NCT04299919
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hepatocellular Carcinoma
Currently open trials in the same condition.
- NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
- NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
- NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
- NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
- NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting
Other The First Affiliated Hospital of Dalian Medical University trials
Trials by the same sponsor.
- NCT07397390 — an Observational Study Evaluting the Effectiveness and Safety of DKutting LL Noval Scoring Balloon Angioplasty for Vesse · enrolling by invitation
- NCT06836999 — Deep Sedation in Catheter Ablation of Atrial Fibrillation · NA · not yet recruiting
- NCT06356701 — Tumor Nutritional Therapy in the First-line Treatment of Stage IV NSCLC · Phase 1 · unknown
- NCT06250842 — Benzodiazepine Impact on Cognitive Function: fNIRs and PET/MRI Study · recruiting
- NCT06056973 — Jinghua Weikang Capsule in the Treatment of Reflux Esophagitis · Phase 4 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04299919 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of Dalian Medical University
- Last refreshed: 9 March 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04299919.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing